A detailed history of Novo Holdings transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Novo Holdings holds 1,000,000 shares of CRNX stock, worth $54.7 Million. This represents 3.57% of its overall portfolio holdings.

Number of Shares
1,000,000
Previous 1,000,000 -0.0%
Holding current value
$54.7 Million
Previous $44.8 Million 14.04%
% of portfolio
3.57%
Previous 3.2%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$42.12 - $51.91 $4.15 Million - $5.12 Million
-98,600 Reduced 8.98%
1,000,000 $44.8 Million
Q1 2024

May 15, 2024

SELL
$34.76 - $46.81 $48,664 - $65,534
-1,400 Reduced 0.13%
1,098,600 $51.4 Million
Q1 2023

May 15, 2023

BUY
$15.31 - $21.1 $5.56 Million - $7.66 Million
362,943 Added 49.24%
1,100,000 $17.7 Million
Q4 2022

Feb 14, 2023

BUY
$15.49 - $19.05 $1.63 Million - $2.01 Million
105,430 Added 16.69%
737,057 $13.5 Million
Q2 2022

Aug 15, 2022

BUY
$16.49 - $27.64 $3.41 Million - $5.71 Million
206,730 Added 48.65%
631,627 $11.8 Million
Q1 2022

May 16, 2022

BUY
$17.15 - $28.31 $7.29 Million - $12 Million
424,897 New
424,897 $9.33 Million
Q2 2021

Aug 16, 2021

SELL
$15.9 - $21.15 $4.31 Million - $5.74 Million
-271,378 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$13.62 - $17.66 $775,318 - $1.01 Million
56,925 Added 26.54%
271,378 $4.25 Million
Q2 2020

Aug 14, 2020

BUY
$13.04 - $23.23 $652,000 - $1.16 Million
50,000 Added 30.4%
214,453 $3.76 Million
Q1 2020

May 15, 2020

BUY
$11.52 - $26.46 $339,194 - $779,088
29,444 Added 21.81%
164,453 $2.42 Million
Q4 2018

Feb 14, 2019

SELL
$22.4 - $35.39 $335,798 - $530,531
-14,991 Reduced 9.99%
135,009 $4.05 Million
Q3 2018

Nov 14, 2018

BUY
$22.66 - $36.8 $3.4 Million - $5.52 Million
150,000 New
150,000 $0

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.94B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Novo Holdings Portfolio

Follow Novo Holdings and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Novo Holdings, based on Form 13F filings with the SEC.

News

Stay updated on Novo Holdings with notifications on news.